Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia

American Journal of Hematology

Volumn 88, Issue 4, 2013, Pages 306-311

  Boudry Labis, Elise ^a,b,c   Roche Lestienne, Catherine ^a,b,c   Nibourel, Olivier ^a,b,c   Boissel, Nicolas ^d   Terre, Christine ^e   Perot, Christine ^f   Eclache, Virginie ^g   Gachard, Nathalie ^h   Tigaud, Isabelle ⁱ   Plessis, Ghislaine ^j   Cuccuini, Wendy ^d   Geffroy, Sandrine ^a   Villenet, Céline ^b,c   Figeac, Martin ^b,c   Leprêtre, Frederic ^b,c   Renneville, Aline ^a,b,c   Cheok, Meyling ^c   Soulier, Jean ^d   Dombret, Hervé ^d   Preudhomme, Claude ^a,b,c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e CENTRE HOSPITALIER DE VERSAILLES   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g AVICENNE HOSPITAL   (France)

^h DUPUYTREN UNIVERSITY HOSPITAL   (France)

ⁱ CENTRE HOSPITALIER LYON SUD   (France)

^j CHU Clemenceau   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFIBROMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FREQUENCY; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMOGENESIS; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; ALLELES; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE DELETION; GENE FREQUENCY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION RATE; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84875586467     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23403     Document Type: Article

References (25)

1. Renneville A, Roumier C, Biggio V, et al. Cooperating gene mutations in acute myeloid leukemia: A review of the literature. Leukemia 2008;22:915-931.
2. Ghanem H, Tank N, Tabbara IA. Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics. Am J Hematol 2012;87:69-77.
3. Estey EH. Acute myeloid leukemia: 2012 Update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:89-99.
4. Walter MJ, Payton JE, Ries RE, et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci USA 2009;106:12950-12955.
5. Akagi T, Ogawa S, Dugas M, et al. Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica 2009;94:213-223.
6. Parkin B, Ouillette P, Wang Y, et al. NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res 2010;16:4135-4147.
7. Suela J, Largo C, Ferreira B, et al. Neurofibromatosis 1, and Not TP53, seems to be the main target of chromosome 17 deletions in de novo acute myeloid leukemia. J Clin Oncol 2007;25:1151-1152; author reply, 1152-1153.
8. Haferlach C, Grossmann V, Kohlmann A, et al. Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases. Leukemia 2012;26:834-839.
9. Rücker FG, Bullinger L, Schwaenen C, et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006;24:3887-3894.
10. Upadhyaya M. Neurofibromatosis type 1: Siagnosis and recent advances. Expert Opin Med Diagn 2010;4:307-322.
11. Reynolds R, Browning G, Nawroz I, et al. Von Recklinghausen's neurofibromatosis: Neurofibromatosis type 1. Lancet 2003;361:1552-1554.
12. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997;336:1713-1720.
13. Steinemann D, Arning L, Praulich I, et al. Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1. Haematologica 2010;95:320-323.
14. Haferlach C, Dicker F, Kohlmann A, et al. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia 2010;24:1065-1069.
15. Thomas X, Raffoux E, Renneville A, et al. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 2010;116:1725-1732.
16. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: Results of the ALFA-9801 study. J Clin Oncol 2010;28:808-814.
17. Itzykson R, Gardin C, Pautas C, et al. Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: A comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica 2011;96:837-844.
18. Leprêtre F, Villenet C, Quief S, et al. Waved aCGH: To smooth or not to smooth. Nucleic Acids Res 2010;38:e94.
19. Hedges DJ, Guettouche T, Yang S, et al. Comparison of three targeted enrichment strategies on the SOLiD sequencing platform. PLoS One 2011;6: e18595.
20. Balgobind BV, Van Vlierberghe P, van den Ouweland AMW, et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 2008;111:4322-4328.
21. Stegelmann F, Bullinger L, Griesshammer M, et al. High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations. Haematologica 2010;95:666-669.
22. Breems DA, Van Putten WLJ, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008;26:4791-4797.
23. Haferlach C, Bacher U, Haferlach T, et al. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: A study in 39 cases of MDS or AML. Leukemia 2011;25:874-877.
24. Chou W, Lei W, Ko B, et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 2011;25:246-253.
25. Score J, Hidalgo-Curtis C, Jones AV, et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012;119:1208-1213.